2023 World Conference on Lung Cancer (Posters)-EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma

EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study compared the outcomes of extensive stage small cell lung cancer (SCLC) and extra-pulmonary small cell carcinoma (EPSCC). EPSCC is a rare cancer with limited research, so treatment strategies are often based on SCLC. The study included patients diagnosed with ES SCLC or EPSCC between 2010 and 2020 from four hospitals in Sydney. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS) and overall response rates (ORR). <br /><br />A total of 383 patients were included in the analysis, with 43 having EPSCC and 340 having SCLC. The EPSCC cases originated from genitourinary, unknown primary, and gastrointestinal sources. Treatment modalities for EPSCC included palliative chemotherapy, radiotherapy, and consolidation chest radiotherapy. Median OS was 6.4 months for EPSCC and 7 months for SCLC. The highest median OS was seen in prostate EPSCC at 25.6 months. <br /><br />There were comparable treatment outcomes between EPSCC and SCLC. Among those who received chemotherapy, median OS was 10.4 months for EPSCC and 8.4 months for SCLC. PFS and ORR were similar between the two groups. The 12-month survival rate was 30% for EPSCC and 21% for SCLC, while the 24-month survival rate was 14% for EPSCC and 6% for SCLC. <br /><br />In conclusion, EPSCC and SCLC have similar OS and treatment outcomes. However, the wide range of OS in EPSCC suggests the need for a better understanding of its genomics and molecular drivers to explore alternative therapeutic options.

Asset Subtitle

Emily Chen

Meta Tag

Speaker Emily Chen

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

extensive stage small cell lung cancer

extra-pulmonary small cell carcinoma

rare cancer

treatment strategies

overall survival

progression-free survival

overall response rates

palliative chemotherapy

radiotherapy

consolidation chest radiotherapy